More NewsRead More
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Today 3:30 EDT
Dividend Highlights/Lowlights for Mar. 10
March 10, 2014
from Dividend Daily
Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met
Today 5:33 EDT
from Financial Content
UPDATE 1-Bayer's Nexavar misses target in liver cancer trial
Today 4:19 EDT
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here